Health technology assessment submissions
Health technology assessment submissions present a technology’s clinical and economic value to bodies advising on reimbursement. Their preparation brings together a value story, clinical evidence, economic analysis and a dossier tailored to the assessment body.
Purpose and the writer’s role
A medicine needs regulatory marketing authorisation and, in single-payer countries, payer reimbursement to reach patients. The assessment submission supports a recommendation about the therapy’s value to patients and the healthcare system, addressing improved efficacy over current care, any safety or dosing advantages that improve adherence and outcomes, and whether the proposed cost is worth those benefits. Unlike the regulatory dossier, it may address relative efficacy and relative effectiveness.
Drug developers need evidence serving both regulatory and assessment agencies; collecting health-economic data within an otherwise typical clinical trial has been explored as one way to coordinate it. Writers must be prepared to contribute to both dossiers and judge where their data and decision-making needs can align.
Submission writing sits between regulatory writing and medical communications. The submission team includes health economists, data analysts, market access professionals and systematic reviewers. Sponsors sometimes prepare submissions in-house, but more typically engage a consultancy for modelling, strategy and dossier creation. The writer’s three main tasks are populating the clinical sections, supporting the health economists and managing the dossier.
The global value dossier and local submission
A global value dossier brings the epidemiological, clinical and economic literature together with the corporate strategy for a product in a given indication in one well-written information resource. It establishes, supports and communicates value through the product lifecycle, first as an internal roadmap and then as the core resource for assessment submissions. Local affiliates adapt it to their country’s medical, pharmacoeconomic and value context, and growing product experience feeds back into refinements of the global dossier.
Value dossiers may be submitted at regulatory approval or earlier, and can support patient access by convincing decision makers of the product’s value to patients and payers. Their four interrelated components are burden of disease, cost and cost-effectiveness, comparative data, and clinical data.
Experience with clinical study reports or other regulatory documents equips writers for the clinical section, although its format usually differs. The breadth of the dossier means they should enlist collaborators with the expertise needed to define and support the value story.
Agency requirements and templates
Each assessment body should be approached as a unique entity and each dossier prepared afresh, because evidence and format requirements differ. A 2013 account noted that even PBAC and NICE took years to clarify their requirements, and that research undertaken after agency advice could subsequently be disallowed.
By 2021, a more generic approach to presenting assessment evidence had helped sponsors organise clearer, more coherent local submissions.
Each agency’s template serves its own review process, making template divergence and the absence of a standard framework important challenges for writers. Templates act as a checklist, allow section-by-section comparisons between dossiers and make details easier to find in sponsor–agency discussions. The template and accompanying user guide should be downloaded afresh for each submission and the guide followed carefully. A clear value message may accelerate assessment and help avoid delaying patient access.
PICO — patient, intervention, comparator, outcome — can organise thoughts and data; it is not widely used as a dossier structure, although its elements remain central to the content. In 2021, writers were advised to understand how EUnetHTA’s Core Model was used to summarise value-dossier evaluations, so that their dossiers fitted its needs. They should become familiar with the product’s European Public Assessment Report when preparing its value dossier.
The clinical section and value story
A good submission has a consistent narrative connecting disease burden and unmet need, patient benefits and any innovation, and the case for good use of healthcare resources. Writing its clinical section requires understanding the disease, current treatment pathway, new treatment and trial data. The team should agree what unmet need the product addresses and what added value it offers patients, caregivers, health services and perhaps society; an early submission may have no established value story to draw on.
The clinical section should give a balanced account of the condition while focusing on needs the product meets. It must support the way the economic model represents the condition: if an HIV model defines health states by CD4+ cell count, the section must explain the count’s relevance to clinical outcomes and quality of life.
The clinical section should define the population for which funding is sought and estimate its size. It should describe the treatment pathway from national guidelines and protocols, the technology’s proposed place in it and any current treatments it would displace. Payers compare against all current treatments, whereas a trial typically has one comparator.
The pivotal trial’s methodology and population should be clear enough for critical appraisal. Within template requirements, the writer should select information that aids the payer’s decision, whether as key data or context; committees have limited time, while their technical reviewers need sufficient detail to understand the case. The clinical study report is usually supplied as a reference.
The section should show how well trial effects represent the local real-world population, comparing patients with country-specific registries or large national or regional case series and exploring differences. Comparator-arm outcomes can be checked against more representative trials or series. Evidence gaps, such as missing head-to-head comparisons or quality-of-life data, should be stated and the response explained. Close cooperation with health economists and the sponsor is needed so that the clinical section supplies the information and argument supporting the economic approach.
Editorial management and post-submission work
Health economists usually draft the economic section, but the writer should review its communication and editing so that concepts are clear and anchored in relevant literature and guidelines. The writer typically also handles formatting, confidentiality marking and the reference pack, and the project plan should allow sufficient time for finalisation. After submission, writers provide clarifications and responses to the assessment body’s questions.
In 2013, a health economist argued that substandard submissions too often led agencies such as NICE to reject products that were not themselves poor. Examples included economics sections that left a NICE committee member unable to identify the model, clinical sections with an unclear target indication, and contradictions between sections indicating poor editorial control.
Short-term evidence and evolving requirements
In 2021, innovative therapies approved through facilitated pathways posed difficulties for value recommendations because of limited long-term data and reliance on surrogate endpoints. Most assessment models were limited in how they integrated short-term data, and assessment bodies and payers were exploring coverage with evidence development, cost sharing and price–volume agreements to reassess value as evidence accumulated. Aligning regulatory and assessment expectations requires writers to adapt as evidence requirements and their own skill needs evolve.
Device value dossiers
A device value dossier contains epidemiology and disease burden, current treatments and their limitations, a systematic review for the procedure, and health economic analysis. Excerpts are often used in reimbursement and assessment submissions.